Clinical Trial Update: Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating SG001 plus chemotherapy ± bevacizumab versus placebo plus chemotherapy ± bevacizumab in PD-L1 positive cervical cancer (CPS ≥1);…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)
• SG001

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) | Phase 3 | Status: NOT_YET_RECRUITING